| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H25BrN4O |
| Molecular Weight | 417.343 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=C(Br)NC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC
InChI
InChIKey=SBHNNNRQZGYOAU-YVEFUNNKSA-N
InChI=1S/C20H25BrN4O/c1-4-25(5-2)20(26)22-12-9-14-13-7-6-8-16-18(13)15(19(21)23-16)10-17(14)24(3)11-12/h6-9,12,17,23H,4-5,10-11H2,1-3H3,(H,22,26)/t12-,17+/m0/s1
| Molecular Formula | C20H25BrN4O |
| Molecular Weight | 417.343 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Bromerguride is an ergot derivative with dopamine antagonistic activity. Bromerguride has been claimed to bind to 5-HT1A receptors and to have 5-HT agonist properties. The neuropharmacological effects caused by the drug in animals were characterized by a central depressant neuroleptic-like symptomatology; the neuroleptic activity of the Bromerguride being at least in the same order of magnitude as haloperidol.
